GlassScriptPhysician profile
Jonathan David Weatherly
NPI 1104698745
$1,729.86
in general payments reported to CMS, 2019-2025
23 companies · $668 in 2025
The $668 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.81 · 2024: $1,040 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.87 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $248.52 | 2024 | Rybrevant, Akeega, Erleada |
| Daiichi Sankyo INC. | $188.38 | 2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $186.89 | 2023-2025 | Calquence, Imfinzi, Tagrisso |
| Jazz Pharmaceuticals INC. | $133.20 | 2025 | |
| Astellas Pharma US INC | $131.93 | 2024-2025 | Vyloy, Padcev |
| Novocure INC. | $128.67 | 2025 | Optune Lua (Novottf-200t) |
| Novartis Pharmaceuticals Corporation | $125.98 | 2024-2025 | |
| Beigene USA, INC. | $125.00 | 2024 | Brukinsa |
| Tersera Therapeutics LLC | $54.24 | 2024-2025 | Zoladex |
| Eisai INC. | $52.56 | 2024 | |
| Incyte Corporation | $50.73 | 2025 | Jakafi, Monjuvi, Pemazyre |
| Emd Serono, INC. | $38.63 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $37.10 | 2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $28.52 | 2024 | |
| Exelixis INC. | $28.14 | 2025 | Cabometyx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.45 | 2024 | Iclusig |
| Merck Sharp & Dohme LLC | $24.83 | 2024 | Keytruda |
| Glaxosmithkline, LLC. | $24.42 | 2025 | Ojjaara |
| Lilly USA, LLC | $21.70 | 2025 | Retevmo, Jaypirca, Verzenio |
| Taiho Oncology, INC. | $21.32 | 2025 | |
| Adc Therapeutics America, INC. | $18.83 | 2025 | |
| Puma Biotechnology, INC. | $17.71 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weatherly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.